Dr Reddy's Labs hits 52-week high after Srikakulam facility gets EIR from USFDA

Dr. Reddy's Laboratories jumped 4.84% to Rs 4020 after the company said its manufacturing plant at Srikakulam in Andhra Pradesh received the Establishment Inspection Report (EIR) from US drug regulator.

Dr. Reddy's Laboratories on Friday (8 May) informed that it has received the Establishment Inspection Report (EIR) for its API (active pharmaceutical ingredient) manufacturing plant located in Srikakulam, Andhra Pradesh from US Food and Drug Administration (USFDA), indicating closure of the audit. The inspection classification of the facility is determined as "Voluntary Action Indicated" (VAI).

The site was issued warning letter in November 2015 after the inspection in 2014, and was under Official Action Indicated classification till now. With this, all facilities under warning letter are now determined as VAI, the company said.

The stock hit an intraday high of Rs 4,099.90 which is also a fresh 52-week high for the counter. Shares of Dr. Reddy's have surged 9.22% in last one month as compared to a 10.95% rise in Nifty Pharma index in the same duration.

Dr. Reddy's Laboratories is an India-based pharmaceutical company. Through its three businesses - pharmaceutical services and active ingredients, global generics and proprietary products - the company offers a portfolio of products and services, including active pharmaceutical ingredients (API), custom pharmaceutical services (CPI), generics, biosimilars, differentiated formulations and new chemical entities.

Powered by Capital Market - Live News